Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.
Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page
- Check3 days agoChange DetectedThe website has been updated to version 2.12.2, with numerous new resources added related to lung cancer, including links to MedlinePlus and clinical trial information.SummaryDifference3%
- Check10 days agoChange DetectedThe website has been updated from version v2.12.0 to v2.12.1.SummaryDifference0.0%
- Check18 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential enhancements or features.SummaryDifference0.1%
- Check25 days agoChange DetectedA new study has been added to evaluate investigational agents in combination with pembrolizumab for treating extensive-stage small cell lung cancer, while a previous study focusing on pembrolizumab in combination with investigational agents has been removed.SummaryDifference53%
- Check40 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.0%
- Check47 days agoChange DetectedThe website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.SummaryDifference0.6%
Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.